1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E Walmsley
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£
17.1200
|
202.000
|
||
£ 17.1200
|
707.000
|
||
£ 17.1200
|
704.000
|
||
£ 17.1200
|
202.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
1815.000
£ 17.1200
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£
17.1200
|
105.000
|
||
£
17.1200
|
149.000
|
||
£
17.1200
|
184.000
|
||
£
17.1200
|
105.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
543.000
£ 17.1200
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
66.000
|
||
£ 17.1200
|
78.000
|
||
£ 17.1200
|
77.000
|
||
£ 17.1200
|
66.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
287.000
£ 17.1200
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr L Miels
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
142.000
|
||
£ 17.1200
|
196.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
338.000
£ 17.1200
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£
17.1200
|
83.000
|
||
£
17.1200
|
145.000
|
||
£
17.1200
|
174.000
|
||
£
17.1200
|
83.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
485.000
£ 17.1200
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R Simard
|
|
b)
|
Position/status
|
President,
Pharmaceuticals Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
63.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
N/A
(single transaction)
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P Thomson
|
|
b)
|
Position/status
|
President,
Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 10 October 2019
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£ 17.1200
|
79.000
|
||
£
17.1200
|
98.000
|
||
£
17.1200
|
102.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
279.000
£
17.1200
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO,
GSK Consumer Healthcare
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
75.000
|
||
$
42.2500
|
74.000
|
||
$
42.2500
|
69.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
218.000
$
42.2500
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dr H Barron
|
|
b)
|
Position/status
|
Chief
Scientific Officer and President, R&D
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
413.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
N/A
(single transaction)
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr J Ford
|
|
b)
|
Position/status
|
SVP and
General Counsel
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
35.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
N/A
(single transaction)
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms K Terrell
|
|
b)
|
Position/status
|
Chief
Digital & Technology Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 10 October 2019 on ADSs held
in the Company's Deferred Annual Bonus Plan.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
42.2500
|
25.000
|
||
$
42.2500
|
87.000
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
112.000
$
42.2500
|
|
e)
|
Date
of the transaction
|
2019-10-14
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: October
15, 2019
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|